Iran Unveils 1st Nat’l Drug for Rare Cancer, Pulmonary Fibrosis
“The drug Midovance, equivalent to the drug Midostaurin, has been produced to treat a specific type of blood cancer called AML or acute myeloid leukemia,” Mohammad Karim Rezayee, the R&D manager of the company, told ANA on the sidelines of the 16th International Nano Technology Exhibition in Tehran.
“This type of drug is a rare disease treatment that was previously only available through imports, and patients faced serious difficulties in obtaining it due to cost and access,” he added.
Rezayee explained that a nanoemulsion system has been used in the formulation of the drug Midvance which is a method that increases the absorption and effectiveness of the drug compared to its traditional forms.
He described Ofenib as the company's second new product, which is designed to treat pulmonary fibrosis and interstitial lung disorders, saying that patients with pulmonary fibrosis have difficulty performing daily activities due to reduced lung function, and the aim of producing this drug is to improve their breathing and physical performance.
The 16th International Nano Technology Exhibition and the First Exhibition of Advanced Technologies of Iran was inaugurated at the Tehran International Fairground.
Running from November 2 to 5, the Nano Exhibition featured over 150 innovative companies showcasing advancements in nanotechnology. Meanwhile, the Exhibition of Advanced Technologies hosted 80 knowledge-based and technological products, attracting visitors, particularly students, researchers, and investors.
4155/v
